GSK plc announced that the U.S. Food and Drug Administration has approved Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, for the once-a-day treatment of anemia due to chronic kidney disease, or CKD, in adults who have been receiving dialysis for at least four months. "Jesduvroq is the first innovative medicine for anaemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral, convenient option for patients in the US with anemia of CKD on dialysis," the company stated. Tony Wood, President and Chief Scientific Officer, GSK, said: "Over the last several decades, there has been little innovation in anemia of CKD. We are proud to have developed Jesduvroq as a new oral treatment where there is a patient desire for more options."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- GSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
- GSK reports Benlysta granted orphan drug designation by FDA
- GSK reports Q4 adjusted EPS 25.8p vs. 23.6p last year
- JMP Securities says older-adult update continues to look encouraging for CureVac
